Literature DB >> 29852767

Returning to work after multimodal treatment in glioblastoma patients.

Daniele Starnoni1, Julien Berthiller2, Tania-Mihaela Idriceanu1, David Meyronet3,4, Anne d'Hombres5, François Ducray6,7, Jacques Guyotat1.   

Abstract

OBJECTIVE Although multimodal treatment for glioblastoma (GBM) has resulted in longer survival, uncertainties exist regarding health-related quality of life and functional performance. Employment represents a useful functional end point and an indicator of social reintegration. The authors evaluated the rate of patients resuming their employment and the factors related to work capacity. METHODS The authors performed a retrospective study of working-age patients treated with surgery and radiochemotherapy between 2012 and 2015. Data were collected before and after surgery and at 6, 12, 18, and 24 months. Employment was categorized according to the French Socio-Professional Groups and analyzed regarding demographic and clinical data, performance status, socio-professional category, radiological features, type, and quality of resection. RESULTS A total of 125 patients, mean age 48.2 years, were identified. The mean follow-up was 20.7 months with a median survival of 22.9 months. Overall, 21 patients (18.3%) went back to work, most on a part-time basis (61.9%). Of the patients who were alive at 6, 12, 18, and 24 months after diagnosis, 8.7%, 13.8%, 15.3%, and 28.2%, respectively, were working. Patients going back to work were younger (p = 0.03), had fewer comorbidities (p = 0.02), and had a different distribution of socio-professional groups, with more patients belonging to higher occupation categories (p = 0.02). Treatment-related symptoms (36.2%) represented one of the main factors that prevented the resumption of work. Employment was strongly associated with performance status (p = 0.002) as well as gross-total removal (p = 0.04). No statistically significant difference was found regarding radiological or molecular features and the occurrence of complications after surgery. CONCLUSIONS GBM diagnosis and treatment has a significant socio-professional impact with only a minority of patients resuming work, mostly on a part-time basis.

Entities:  

Keywords:  GBM = glioblastoma; HRQOL = health-related quality of life; KPS = Karnofsky Performance Status; OS = overall survival; employment; glioblastoma; multimodal treatment; return to work

Mesh:

Substances:

Year:  2018        PMID: 29852767     DOI: 10.3171/2018.3.FOCUS1819

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  11 in total

1.  Preoperative predictive factors affecting return to work in patients with gliomas undergoing awake brain mapping.

Authors:  Akihito Yoshida; Kazuya Motomura; Atsushi Natsume; Lushun Chalise; Kentaro Iijima; Daisuke Hara; Izumi Kadono; Kenji Wakai; Toshihiko Wakabayashi
Journal:  J Neurooncol       Date:  2019-12-18       Impact factor: 4.130

2.  Quality of life following awake surgery depends on ability of executive function, verbal fluency, and movement.

Authors:  Riho Nakajima; Masashi Kinoshita; Hirokazu Okita; Mitsutoshi Nakada
Journal:  J Neurooncol       Date:  2021-11-20       Impact factor: 4.130

3.  Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.

Authors:  Munki Choo; Van-Hieu Mai; Han Sun Kim; Dong-Hwa Kim; Ja-Lok Ku; Sang Kook Lee; Chul-Kee Park; Yong Jin An; Sunghyouk Park
Journal:  Acta Pharmacol Sin       Date:  2022-09-13       Impact factor: 7.169

4.  Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests.

Authors:  James L Rogers; Julianie De La Cruz Minyety; Elizabeth Vera; Alvina A Acquaye; Samuel S Payén; Jeffrey S Weinberg; Terri S Armstrong; Shiao-Pei S Weathers
Journal:  Neurooncol Pract       Date:  2022-02-17

Review 5.  Should Neurosurgeons Try to Preserve Non-Traditional Brain Networks? A Systematic Review of the Neuroscientific Evidence.

Authors:  Nicholas B Dadario; Michael E Sughrue
Journal:  J Pers Med       Date:  2022-04-06

6.  Complete response to therapy: why do primary central nervous system lymphoma patients not return to work?

Authors:  Greta Wiemann; Milena Pertz; Uwe Schlegel; Patrizia Thoma; Thomas Kowalski; Sabine Seidel
Journal:  J Neurooncol       Date:  2020-07-31       Impact factor: 4.130

7.  Patient-reported cognitive function before and after glioma surgery.

Authors:  Stine Schei; Ole Solheim; Øyvind Salvesen; Tor Ivar Hansen; Lisa Millgård Sagberg
Journal:  Acta Neurochir (Wien)       Date:  2022-06-06       Impact factor: 2.816

8.  Employment and Work Ability of Persons With Brain Tumors: A Systematic Review.

Authors:  Fabiola Silvaggi; Matilde Leonardi; Alberto Raggi; Michela Eigenmann; Arianna Mariniello; Antonio Silvani; Elena Lamperti; Silvia Schiavolin
Journal:  Front Hum Neurosci       Date:  2020-10-29       Impact factor: 3.169

9.  Quality of life and return to work and sports after spinal ependymoma resection.

Authors:  Vicki M Butenschoen; Till Gloßner; Isabel C Hostettler; Bernhard Meyer; Maria Wostrack
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

10.  Return to work following diagnosis of low-grade glioma: A nationwide matched cohort study.

Authors:  Isabelle Rydén; Louise Carstam; Sasha Gulati; Anja Smits; Katharina S Sunnerhagen; Per Hellström; Roger Henriksson; Jiri Bartek; Øyvind Salvesen; Asgeir Store Jakola
Journal:  Neurology       Date:  2020-06-15       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.